Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders
Citation Manager Formats
This article has a correction. Please see:

Article Information
- First Published September 26, 2018.
Author Information
- Michael Levy, MD, PhD
- Michael Levy, MD, PhD
Asterias, Chugai, Alexion
NONE
NONE
Editorial Board member of Multiple Sclerosis and Related Disorders
1. Aquaporin-4 sequence that elicits pathogenic T cell response in animal model of neuromyelitis optica. 2. Description: patent covers use of peptide for diagnostic and therapeutic developments.
NONE
NONE
Guidepoint Global; Gerson Lehrman Group; Cowen Group
NONE
NONE
NONE
Viropharma/Shire, Acorda, ApoPharma and Sanofi, Genzyme, Alnylam, Alexion, Terumo BCT
National Institute of Neurological Diseases and Stroke
NONE
Guthy-Jackson Charitable Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Correspondence
Dr. Levy mlevy{at}jhmi.edu
Article usage
Cited By...
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.